# Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct07159217/  
OnCo record `nct07159217` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of disitamab vedotin, pembrolizumab, camrelizumab and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, not yet recruiting.

## Summary

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT07159217 by Peking Union Medical College Hospital, with a registry enrolment figure of 65 participants, started 2025-08-30 and due to reach its primary completion in 2027-05-31. Interventions recorded: Disitamab Vedotin, Lenvatinib, Pembrolizumab, Toripalimab, Camrelizumab. Conditions listed: Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors. Gallbladder cancer is named in the registry entry: "3. Histologically or cytologically confirmed unresectable locally advanced or metastatic biliary tract cancer (BTC), including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07159217
- Phase: 2
- Setting: A Prospective Exploratory Phase II Study of Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for the Treatment of HER2-positive Advanced Biliary Tract Cancer
- Sponsor: Peking Union Medical College Hospital
- Enrolled: 65

## Sources

- ClinicalTrials.gov NCT07159217: https://clinicaltrials.gov/study/NCT07159217

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07159217.json